- Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases.
|
|
- Kristin Young
- 5 years ago
- Views:
Transcription
1 암의면역치료 권병세
2 Immunotheraphy - Defined as approaches that enhance, suppress or modify the immune system to treat or cure diseases. - Applied for the treatment of cancer, autoimmune diseases, transplant rejection, and chronic infection. - Little or no side effects. - Take advantage of inherent properties of immune system. - Selectivity.
3 Cancer Immunotherapy 1. Active a. Vaccine Tumor cells DNA b. Idiotype antibodies 2. Passive a. mab b. Cells
4 mab therapeutics 1. Direct killing of Cancer cells - ADCC and CDC Ex) anti-cd20, anti-her2 2. Immunomodulation - Enhance effector mechanisms Ex) anti-ctla4, anti-4-1bb (CD137)
5 Antibody Therapeutics
6 Immunomodulatory mab therapeutics 1. Ipilimumab (anti-ctla4) 2. Anti-4-1BB 3. Anti-PD1 4. Anti-PDL1 5. Anti-AITR
7 Immunomodulatory mab Therapeutics Anti-4-1BB Anti-CTLA4 Anti-4-1BB Anti-CTLA4 4-1BB Lymph node T cells Cancer -specific T APC cancer Cancer antigen 7
8 ICAM-1 CD48/58 ICOS-L B7-1 LFA-1 CD2 ICOS CD28 Positive costimulation B7-2 CTLA-4 PD-L1 PD-L2 PD-1? Negative costimulation HVEM BTLA-4 APC MHC TCR T cell LIGHT HVEM GITR-L GITR IgG superfamily CD40 CD40L TNF superfamily CD70 CD27 Positive costimulation 4-1BB-L 4-1BB CD30-L CD30 OX40-L OX40
9 Adoptive Immune Cell Therapeutics
10 I-1. Adoptive Immunotherapy Adoptive Immunotherapy DCs NKs CTLs Tumor killing mechanism CTL Induction Direct killing Direct killing Immunological Memory + -/+ +++ Intra-subset regulation >7 subsets yes >2 subsets yes ~2 subsets no Ag specificity Specific Non-specific Specific Proliferation in vivo Peripheral % < 1% 1-5% 10-30% Patient preconditioning No Yes Yes Production procedure Simple Simple Ag-specific T cell selection 10
11 Adoptive T cell therapy of NCI Gattinoni L. Nat Rev Imm 2006 Steve Rosenberg & Nick Restifo NCI, NIH, USA
12 Lymphodepletion 1. Homeostatic lympho-proliferation (Tan et al., JEM 195:1523, 2002; Gattinoni et al., JEM 202:907, 2005) 2. Preconditioning of cancer patient (Rosenberg et al., Clin Cancer Res 17:4550, 2011)
13 Survival of patients with metastatic melanoma treated with autologous tumor-infiltrating lymphocytes and IL-2 : Cross-clonal targeting and modification of microenvironment No TBI (43 pts) OR: 49% (CR:13%) Clin Cancer Res 17:4550, 2011 TBI (200cGy) (13 pts) OR: 52% (CR:20%) TBI (1200cGy) (18 pts) OR: 72% (CR:56%)
14 1. To aim cross-clonal common targets to overcome intratumoral clonal heterogeneity. 2. To modify immunosuppressive tumor microenvironment.
15 CTL therapeutics (Clinical Experience) Polyclonal CTLs Hurdle 1 PBMC OKT3 Polyclonal CTLs including some Agspecific CTLs Antigen-specific CTLs PBMC Lymphoblastoid Cell Lines (LCL) Antigen-specific CTLs PBMC Ag-pulsed DCs Antigen-specific CTLs PBMC Ag-pulsed Allogeneic APCs Antigen-specific CTLs
16 Solution Mixed Lymphocyte Peptide Culture (MLPC)
17 Problems with Purification of tumor-specific T cells Hurdle 2 Tumor T cell repertoire a b c d e.. 1. pmhc multimers - Lack of available reagents: peptide and MHC - TCR down regulation 2. Functional separation - cytokines or degranulation - Detect only subsets of T cells
18 T 세포의다양성 T cell diversity 유전자조합가능한 TCR: ~10 15 TCR 종류 : 총 T 세포수 : ~10 12
19 I-4. Cacer Immunotherapy at National Cancer Center 4-1BB (CD137) 4-1BB Cancer cells APC MHC I TCR Anti-tumor CD8 T cells Anti-apoptosis Proliferation htert WT1 NY-ESO1 Memory formation Longevity 19
20 pcmv pp65 Cell % 4-1BB pcmv pp65 4-1BB expression and Expansion of CMV + CD8 + T cells A #1 #2 #3 #4 # CD8 B 1 day 3 day 5 day 7 day 14 day C 100 pcmv + CD8 + T BB + CD8 + T CD CD Incubation time (day)
21 pcmv pcmv 4-1BB 4-1BB 4-1BB pcmv 4-1BB 4-1BB expression upon restimulation on Day 14 A Before 1 After restimulation Exp #1 Exp #2 Exp # B R1 Exp #1 Exp # R1 CD8 54 CD R2 FSC R2 CD CD8 CD8 CD8
22 pcmv pcmv + CD8 + T (%) Recovery rate (%) 4-1BB pcmv 4-1BB Use of 4-1BB for selection of CMV + CD8 + T cells A R1 Exp #1 Exp # R1 R2 FSC R2 CD CD8 B Panning CD8 Bead Exp #1 Exp #2 C Bead Panning D Bead Panning
23 I-4. Cancer Immunotherapy at National Cancer Center Adoptive 4-1BBCTL Therapy 암항원 (TAAs) Peptide(s) PBMC 에암항원을첨가하여배양 4-1BB 암항원에반응하는 T 세포의 4-1BB 발현 항 -4-1BB 항체를이용한암항원특이적 T 세포의분리 분리된 T 세포의대량배양 말초혈액 PBMC 분리 암환자투여 Pre-conditioning 23
24 I-4. Cancer Immunotherapy at National Cancer Center Clinical Trials at NCC ( 국립암센터 ) Name: EBViNT Cell; EBV-induced NCC T Cell Indications: Standard therapy-failed EBV-positive Cancers; Lymphomas, Gastric Cancers, Nasopharyngeal Carcinomas Date of Approval:
25 I-4. Cancer Immunotherapy at National Cancer Center EBViNT Cell Dose II (1/2 bag; cells, NCC-02 HCS) NCC-02 HCS 62 year-old, male ECOG PS 1 EBViNT Cells Lot # Ag HCS-CT HLA-A*24-restricted EBV/LMP2A Hodgkin's disease Prior chemotherapy regimen: #2 25
26 I-4. Cancer Immunotherapy at National Cancer Center EBViNT Cell Dose II (1 bag; cells, NCC-03 KMS) Rt lower leg lesion NCC-03 KMS 63 year-old, female 4 weeks after EBViNT Therapy ECOG PS 1 Extranodal NK/T cell lymphoma nasal cavity: EBV-ISH negative Rt lower leg mass: EBV-ISH positive r/o renal abscess, r/o tumor 6 months after EBViNT Therapy Prior chemotherapy regimen: #1 EBViNT Cells Lot # Ag KMS-CT HLA-A*24-restricted EBV/LMP2A 9 months after EBViNT Therapy
27 Benefits Complete durable regression can be induced. No/minimum toxicity. Epitope Spreading at a full dose of CTL. High rate of manufacturing success (7/8). 27
28 I-5. Lessons from the NCC Cancer Immunotherapy Strong 2 nd immune responses are found in the patient with complete regression Weak 2 nd response Strong 2 nd response No 2 nd response 28
29 I-5. Lessons from the NCC Cancer Immunotherapy Epitope spreading is required for the complete regression of tumor Tumor cells Cancer Heterogeneity IFN-g Driver CTLs kill target tumor cells Release of new tumor Ags Suppressive tumor microenvironment Epitope Spreading IFN-g-mediated Driver CTL-dependent Strong 2 nd immune response Intra- & inter-molecular epitope spreading Overcome Ag loss & MHC downregulation 29
30 Measures to improve NCC CTL Therapy 1. Effective in vivo expansion and Memory - CTL Subset and Homeostatic lymphoproliferation. 2. Immunosuppressive tumor microenvironment. 3. Immune cell suppressors in patient serum. 4. Manufacturing period of NCC CTL. 5. Immunosuppressive NK, myeloid cells and RBC during induction phase. 6. Why PD in NPC?
31 The inverse relationship of in vitro and in vivo effector functions of adoptively transferred T cell subsets
32 % Tcm CD8 T (CD45RO + CD62L + ) # CD8 T cells Production of Tcm NCC CTL IL-2+PBS IL-7+PBS IL-15+PBS IL-21+PBS IL-2+IL-7 IL-2+IL-15 IL-2+IL-21 IL-7+IL-15 IL-7+IL-21 IL-15+IL IL-2+PBS IL-7+PBS IL-15+PBS IL-21+PBS IL-2+IL-7 IL-2+IL-15 IL-2+IL-21 IL-7+IL-15 IL-7+IL-21 IL-15+IL-21
33 CD8 CD8 In vivo effect of cytokines on adoptively-transferred CD8 + T cells gc cytokine-induced CMV + CD8 T ( cells/ i.v./ mice) Analysis Rag2gc DKO mice IL-2 (IL-7 or IL-21) (50,000IU/i.p./mice) IL-2+PBS IL-7+PBS IL-21+PBS IL-2+IL-7 IL-2+IL-21 IL-7+IL-21 IL-2 CD4 + IL-2 IL-2+PBS IL-7+PBS IL-21+PBS IL-2+IL-7 IL-2+IL-21 IL-7+IL CD4
34 Modification of Cancer Microenvironment Cancer Cells CTL Lymphodepletion Immune Sppressors Cancer CTL
35 Shortening of production period of NCC CTL Modification 1 (shortening of restimulaton and rapid expansion periods) A. Original protocol (50cc) (50cc) (100cc) (300cc) (500cc) culture medium days Induction phase Restimulation Isolation Rapid expansion B. Test protocol (-2 days) (-4 days) (200cc) (300cc) (500cc) days Induction phase Restimulation Isolation Rapid expansion Modification 2 (increase of number of seed cells) - CD8 T cell number: current (5 x 10 5 cells per bag) - suggested ( 1 x 10 6 cells per bag) - Culture bag number: current (1 ~ 2 bags) - suggested ( 3 bags) A. Original protocol (50cc) (50cc) (100cc) (300cc) (500cc) culture medium days Induction phase Restimulation Isolation Rapid expansion B. Test protocol (-2 days) (-7 days) (200cc) (300cc) (500cc) days Induction phase Restimulation Isolation Rapid expansion
36 IV-1. 제 1 세부과제 - 선행연구 Epitope Screening for 4-1BBCTLs Cancer Antigens Response rate (%) EBV + cancers Hematologic Oncology Clinic EBV LMP2a (18) ~ 81% Glioblastomas Neuro-Oncology Clinic WT1 (20) ~ 68% Pancreatic cancers Center for Liver Cancer htert (25) ~ 55% Lung cancers Sarcomas Center for Lung Cancer Orthopedic Oncology Clinic htert (25) WT1 (20) MAGE-A3 (24) NY-ESO-1 (20) MAGE-A3 (24) ~ 60% ~ 70% ~ 70% ~ 53% ~ 58% NY-ESO-1 (20) ~ 70% Ovarian cancers OY-TES-1 (10) ~ 44% Center for Uterine Cancer Cervical cancers HPV (23) ~ 40% Gastric cancers Center for Gastric Cancer htert (25) ~ 70% Prostate Cancers Center for Prostate Cancer PSMA TARP Planned Breast Cancers Center for Breast Cancer NY-ESO-1 Planned Solid tumors Mutated tumor Ags Planned 36
37 Clinical Trial with WTiNT Cell Name WTiNT Cell; WT1-induced NCC T Cell Indications Standard therapy-failed glioblastoma pateints Data of Approval
38 Clinical Trial with TERTiNT Cell Name TERTiNT Cell; htert-induced NCC T Cell Indications Standard therapy-failed solid cancers; Lung cancers, Gastric cancers, Pancreatic cancers & Melanomas Data of Approval Under IND filing
39 Plans for future clinical trials Antigen Cell type Product Name KFDA approval Condition for Phase I clinical trial Indication EBV/LMP2A CD8 T EBViNT Cell EBViNT Cell alone WT-1 CD8 T WTiNT Cell WTiNT Cell + TMZ (lymphodepletion) htert CD8 T TERTiNT Cell - TERTiNT Cell + CTX + IL-2 NY-ESO-1 CD8 T ESOiNT Cells - ESOiNT Cell + CTX + IL-2 MAGE-A3 CD8 T MAGE3iNT Cells - HPV E6/E7 CD8 T HPViNT Cells - MAGE3iNT Cell + CTX + peptide vaccine HPViNT Cell + CTX + peptide vaccine Lymphomas Nasopharyngeal cancers Gastric cancers Glioblastoma, Leukemias Lung, gastric, & pancreatic cancers Sarcomas Ovarian cancers Lung cancers Sarcomas Cervical cancers
40 Milestones for the NCC T Cell Therapeutics Establishment of CTL production protocol Installation of cgmp facility, NCC cgmp translation of production protocol IND filing of EBViNT cells Pilot production Phase I of EBViNT Cells, Lymphomas KFDA inspection of cgmp facility, NCC IND filing of WTiNT cells Phase I of WTiNT Cells, Glioblastomas IND filing of TERTiNT cells Thank Everyone Involved!!
41 Limitations and Supplement Approaches to NCC CTLs Limitations 1. HLA restriction 2. Peripheral repertoire restriction 3. Manufacturing period Approaches to overcome the limitations 1. High avidity TCR gene-modified T cells 2. CAR (chimeric antigen receptor)-modified T cells
42 IV-1. 제 1 세부과제 High avidity TCR-expressing CTL (etcl) and Chimeric Antigen Receptor (CAR)-modified CTL 42
43 IV-1. 제 1 세부과제 자가유래 T 세포치료제의제한점 1. 비정상적혈액상태 T 세포치료제제조불가능 2.Mixture of low & high avidity TCR T 세포치료제효력감소 3. 긴제조공정 피험자사망시치료불가능 High avidity TCR 유전자확보 1.T 세포치료제적용환자비율증가 적용대상증가 2. 강력한 1차항암면역반응유도가능 완치효과증가 3. 제조공정단축 적용대상증가 43
44 High Avidity TCR Gene-modified T Cells
45 IV-1. 제 1 세부과제 추진전략및방법 I Cloning epitope-specific CD8 T cells 45
46 IV-1. 제 1 세부과제 추진전략및방법 II Development of high avidity TCR mini-library Single cell cloning Epitope-specific CD8 T (10 50 clonotypes) htert, WT1, NY-ESO1 Mutated tumor Ags ~4 weeks Single clone selection TCR mini-library Non-mutated tumor Ag htert WT1 NY-ESO1 Mutated tumor Ag p53, p53, k-ras, b-raf, b- Selection In vitro tumor killing assay etcr T cell production TCRa/b cloning Recombinant virus expressing the TCRa/b gene catenin, PIK3CA, JAK2 Discard 46
47 IV-1. 제 1 세부과제 추진전략및방법 III Personalized etcr T cells #1 #2 #3 #4 #5 A*02 A*24 A*02 A*24 A*02 A*24 TCRa/b Mini-library hter T WT1 NY-EOS1 TCRa/b 유전자도입 T 세포분리 TCR 유전자도입세포분리 대량증식 투여 암조직또는혈액 - 적용대상증가 - 강력한 1 차항암반응 - 짧은제조기간 47
48 IV-2. 제 2 세부과제 Chimeric Ag Receptor T cells Perforin Granzymes Ab ScFv Signaling 4-1BB CD3z Antigen Cancer Stem Cells CD8 + T cells IFN-g, TNF-a, IL-2 48
49 MAbs to produce CAR-modified T cells 1. Anti-MVR (malignancy variant receptor) 2. Anti-CSCR (cancer stem cell receptors)
50 CD19 Anti-MVR-BBz Chimeric Antigen Receptor Construct A ALL patient s PBMCs Surface 951/control Isotype Anti-MVR 951/MVR Anti-MVR-BBz CD8-leader (GLY 4 SER) 3 linker CD8-hinge/TM 4-1BB-Cyto CD3z-Cyto VH VL Anti-MVRscFv Signaling domain Anti-MVRscFv Lentiviral vector pelps-mvr-bbz 4-1BB CD3z MVR-BBz
51 Count Specific tumor cell lysis by anti-mvr CAR-T cells. BC-1 B-lymphoma CFSE Low LCL B-lymphoma CFSE High Anti- MVR No T cells Con T cells Anti-MVR-T cells 4 hrs 18 hrs CFSE
52 Summary I BB-based CTL therapeutics has been developed. 2. EBV-specific CTLs showed a therapeutic effect against NK/T lymphoma. 3. Effective cancer therapy requires both active tumor killing and nullification of tumor-promoting factors. 4. Improvement of 4-1BB CTL therapy Conversion of Treg to Teff Enrichment of central memory CD8 + T cells Shortening manufacturing period 5. etcr-ctl and CAR-modified CTL can overcome some limitations associated with peripheral repertoire-dependent CTL therapy
Cancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationDEVELOPMENT OF CELLULAR IMMUNOLOGY
DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationAdoptive Cell Therapy: Treating Cancer
Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationCytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands
Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?
More informationAdoptive T Cell Therapy:
Adoptive T Cell Therapy: A Paradigm for Combination Strategies Cassian Yee MD Professor Melanoma Medical Oncology Immunology Director Solid Tumor Cell Therapy cyee@mdanderson.org skype name: tcelltherapy
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationAdoptive Cellular Therapy SITC Primer October 2012
Adoptive Cellular Therapy SITC Primer October 2012 Cassian Yee MD Member Fred Hutchinson Cancer Research Center Program in Immunology Clinical Research Division Professor University of Washington Division
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationEnhancing the Clinical Activity of HER2/neu Specific T Cells. William Gwin, MD Internal Medicine, Resident University of Washington
Enhancing the Clinical Activity of HER2/neu Specific T Cells William Gwin, MD Internal Medicine, Resident University of Washington Immunotherapy and Cancer Cancer vaccines were originally used in melanoma
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationCAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris
CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th 2018 - Paris Cellectis, 05-APR-2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationAdoptive cell therapy using genetically modified antigen-presenting cells
Adoptive cell therapy using genetically modified antigen-presenting cells Naoto Hirano Ontario Cancer Institute Princess Margaret Cancer Centre University of Toronto UofT-USP Oncology Conference November
More informationImmune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine
Immune Tolerance Kyeong Cheon Jung Department of Pathology Seoul National University College of Medicine Immune tolerance Unresponsiveness to an antigen that is induced by previous exposure to that antigen
More informationT Cell Activation, Costimulation and Regulation
1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family
More informationTrial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor
Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationVISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School
VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationDendritic cells in cancer immunotherapy Aimin Jiang
Dendritic cells in cancer immunotherapy Aimin Jiang Feb. 11, 2014 Dendritic cells at the interface of innate and adaptive immune responses Dendritic cells: initiators of adaptive immune responses Dendritic
More informationCancer Immunotherapy. What is it? Immunotherapy Can Work! 4/15/09. Can the immune system be harnessed to fight cancer? T CD4 T CD28.
Cancer Immunotherapy CANCER BIOLOGY April 15, 2009 Can the immune system be harnessed to fight cancer? Can the immune system see cancer? What is the best way to turn on the immune system to fight cancer?
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationCELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION
CELLULAR AND MOLECULAR REQUIREMENTS FOR REJECTION OF B16 MELANOMA IN THE SETTING OF REGULATORY T CELL DEPLETION AND HOMEOSTATIC PROLIFERATION Justin Kline 1, Long Zhang 1, and Thomas F. Gajewski 1,2 Departments
More informationA Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients
A Multifaceted Immunomonitoring to Identify Predictive Biomarkers for the Clinical Outcome of Immunotherapy-Treated Melanoma Patients Immunotherapy Biomarkers: Overcoming the Barriers NIH, Bethesda, April
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells
Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard
More informationNovel Approaches to CAR-T Cell Platform
Novel Approaches to CAR-T Cell Platform Vita Golubovskaya, Ph.D. Director, R&D Promab Biotechnologies 3 rd CAR-TCR Summit 2017 S E P T E M B E R 5-7 B O S T O N Novel Approaches To CAR-T Cell Platform
More informationRadiation Therapy as an Immunomodulator
Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationThe next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)
The next steps for effective cancer immunotherapy and viral vaccines Peter Selby FACP(UK) Richard Alan Steve Sasha Matt Nav Vile Melcher Griffin Zougman Bentham Vasudev Adel Nick Gemma Liz Samson Hornigold
More informationFOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1
1 Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF FOCiS 2 Lecture outline Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationCancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
More informationImmunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia
Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer
More informationImmunotherapy of Prostate Cancer
Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines
More informationIMMU 7630 Fall 2018 TUMOR IMMUNOLOGY
TUMOR IMMUNOLOGY CANCER. About 610,000 people in the United States will die of cancer in 2018 1. It is the second leading cause of death, after heart disease. After accidents, it is the second leading
More informationCellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU
Cellular Immune response Jianzhong Chen, Ph.D Institute of immunology, ZJU Concept of adaptive immune response T cell-mediated adaptive immune response I. Concept of immune response A collective and coordinated
More informationTherapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler
Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler Goal of Immunotherapy Boosting the low level anti-tumor immune
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationCBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology
CBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology Peter Bross, MD Office of Cellular, Tissue and Gene Therapies, CBER FDA IOM Policy Issues in the Clinical Development
More informationOverview 4/11/2013. Cell Kinetics in Adoptive Cell Therapy. April 11, 2013
Cell Kinetics in Adoptive Cell Therapy April 11, 2013 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationCancer immunotherapy with oncolytic viruses: more than just lysis
Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationTumor immunology. Tried to make things a simple as they can get,,, hope that u enjoy it! ال تخافوا بس أربع صفحات وشوي
Tumor immunology Tried to make things a simple as they can get,,, hope that u enjoy it! ال تخافوا بس أربع صفحات وشوي Tumors can occur, they can be considered as something foreign that should be dealt with
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins
More informationT Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate
More informationStem Cell Sources 2/22/13. Cellular Therapy Today and Tomorrow. Cellular Therapy in HCT. Bone Marrow
2/22/13 Cellular Therapy Today and Tomorrow Robert S. Negrin, MD Division Chief, Stanford Bone and Marrow Transplant Program Professor of Medicine Cellular Therapy in Clinical Medicine Established Hematopoietic
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More information5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)
Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationEndogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationEmerging Concepts of Cancer Immunotherapy
Emerging Concepts of Cancer Immunotherapy Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Immune Cell Infiltrate in Primary
More informationAdaptive Immunity. Jeffrey K. Actor, Ph.D. MSB 2.214,
Adaptive Immunity Jeffrey K. Actor, Ph.D. MSB 2.214, 500-5344 Lecture Objectives: Understand role of various molecules including cytokines, chemokines, costimulatory and adhesion molecules in the development
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationImm 532 2/25/16. Tumor Immunology. Phil Greenberg
Imm 532 2/25/16 Tumor Immunology Phil Greenberg Tumor Immunology Study of the interactions between the immune system and cancer - antigenic properties of tumor cells - host immune response to tumor cells
More informationImmunotherapy of HNC: immune mechanisms and therapeutic targets
Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationMelanoma Bridge Meeting
Melanoma Bridge Meeting Improving Adoptive Immune Therapy with Genetically Engineered T cells David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH 3 December 2015 Adoptive T Cell Therapy: Dose
More informationGeneral Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center
General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses
More informationAbstract #163 Michael Kalos, PhD
LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract
More informationNew insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre
New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures
More informationAdministration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas
Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-ß to Patients with EBV-Associated Lymphomas CM. Bollard, G Dotti, S Gottschalk, E Liu, A Sheehan, M Mims, H Liu, AP. Gee,
More informationAdvances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014
Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus
More informationBlocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-
Supplementary Methods Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD- L1 (10F.9G2, rat IgG2b, k), and PD-L2 (3.2, mouse IgG1) have been described (24). Anti-CTLA-4 (clone
More informationManuscript: OX40 signaling is involved in the autoactivation of CD4 + CD28 - T cells and contributes to pathogenesis of autoimmune arthritis
Manuscript: OX40 signaling is involved in the autoactivation of CD4 + CD28 - T cells and contributes to pathogenesis of autoimmune arthritis Vincent Laufer Rheumatology JC October 17 Disclosures NIH 2
More informationT cell manipulation of the graft: Yes
T cell manipulation of the graft: Yes J.H. Frederik Falkenburg Department of Hematology L M U C Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for non-malignant disorders: no need for anti-tumor
More informationOverview 3/31/2016. Cell Kinetics in Adoptive Cell Therapy. March 31, 2016
Cell Kinetics in Adoptive Cell Therapy March 31, 2016 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationCell Kinetics in Adoptive Cell Therapy. March 31, 2016
Cell Kinetics in Adoptive Cell Therapy March 31, 2016 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH 1 Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationReview Article Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
Hindawi Journal of Immunology Research Volume 2017, Article ID 5210459, 13 pages https://doi.org/10.1155/2017/5210459 Review Article Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological
More informationPractical Solution: presentation to cytotoxic T cells. How dendritic cells present antigen. How dendritic cells present antigen
Christian Kurts Institutes of Molecular Medicine and Experimental Immunology University of Bonn, Germany - presentation and (CTL) activation - I presentation and CD4 + T cell (Th cell) activation Different
More informationAllergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.
Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared
More information